Lista de obras -

A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia

artículo científico publicado en 2007

Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?

artículo científico publicado en 2012

An overview of the extra-lipid effects of rosuvastatin.

artículo científico publicado en 2008

Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects.

artículo científico publicado en 2009

Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.

artículo científico publicado en 2008

Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

artículo científico

Clinical relevance of central blood pressure - a critical review.

artículo científico publicado en 2016

Clopidogrel vs. aspirin treatment on admission improves 5-year survival after a first-ever acute ischemic stroke. data from the Athens Stroke Outcome Project.

artículo científico publicado en 2011

Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.

artículo científico publicado en 2012

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects

scientific article published on 09 November 2020

Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.

artículo científico publicado en 2011

Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease

artículo científico publicado en 2013

Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects.

artículo científico publicado en 2007

Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2

artículo científico publicado en 2007

Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension

artículo científico publicado en 2011

Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.

artículo científico publicado en 2009

Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.

artículo científico publicado en 2007

Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough?

artículo científico publicado en 2012

Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia.

artículo científico publicado en 2012

Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects

scientific article published on 01 January 2019

Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome

artículo científico publicado en 2012

Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.

artículo científico publicado en 2007

Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels

scientific article published on 02 January 2013

Effects of benchmarking on the quality of type 2 diabetes care: results of the OPTIMISE (Optimal Type 2 Diabetes Management Including Benchmarking and Standard Treatment) study in Greece.

artículo científico

Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study

artículo científico publicado en 2010

Emerging drugs for hyperlipidaemia: an update

artículo científico

Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity

artículo científico publicado en 2012

Ezetimibe - a new approach in hypercholesterolemia management.

artículo científico publicado en 2012

Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress

artículo científico publicado en 2011

Fenofibrate and the kidney: an overview.

artículo científico

Gender differences in the epidemiology, clinical presentation, prevention, and prognosis of acute coronary syndromes

artículo científico publicado en 2013

Hemostatic factors and the metabolic syndrome

scientific article published on 01 November 2013

How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.

artículo científico publicado en 2014

Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women.

artículo científico publicado en 2008

Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome.

artículo científico publicado en 2007

Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.

artículo científico publicado en 2014

Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial

scientific article published on 17 September 2018

Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease

artículo científico publicado en 2012

Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias.

artículo científico

Modelling eating practices in non-fatal acute coronary syndrome or stroke development: a case/case-control study.

artículo científico publicado en 2012

New-onset extremely low levels of high-density lipoprotein cholesterol

artículo científico publicado en 2012

Obstructive sleep apnoea syndrome and cardiovascular risk.

artículo científico publicado en 2012

Pioglitazone and cancer: angel or demon?

artículo científico

Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia including Registries

artículo científico publicado en 2018

Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?

scientific article published on 18 November 2019

Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia

scientific article published on 01 November 2006

Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose.

artículo científico publicado en 2009

Statins and mortality: the untold story.

artículo científico publicado en 2017

Statins and their increased risk of inducing diabetes

artículo científico

Targeting cardiovascular risk: the impact of age, gender and compliance to treatment

scientific article published on 02 August 2012

The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose.

artículo científico publicado en 2014

The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

artículo científico publicado en 2007

Therapeutic options for statin-intolerant patients

artículo científico publicado en 2012

Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)

artículo científico publicado en 2006

Variable effects of statins on glucose homeostasis parameters and their diabetogenic role.

artículo científico publicado en 2015

Lista de obras de

A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia

Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?

An overview of the extra-lipid effects of rosuvastatin.

Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects.

Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.

Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Clinical relevance of central blood pressure - a critical review.

Clopidogrel vs. aspirin treatment on admission improves 5-year survival after a first-ever acute ischemic stroke. data from the Athens Stroke Outcome Project.

Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects

Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.

Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease

Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects.

Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2

Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension

Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.

Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.

Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough?

Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia.

Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects

Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome

Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.

Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels

Effects of benchmarking on the quality of type 2 diabetes care: results of the OPTIMISE (Optimal Type 2 Diabetes Management Including Benchmarking and Standard Treatment) study in Greece.

Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study

Emerging drugs for hyperlipidaemia: an update

Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity

Ezetimibe - a new approach in hypercholesterolemia management.

Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress

Fenofibrate and the kidney: an overview.

Gender differences in the epidemiology, clinical presentation, prevention, and prognosis of acute coronary syndromes

Hemostatic factors and the metabolic syndrome

How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.

Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women.

Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome.

Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.

Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial

Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease

Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias.

Modelling eating practices in non-fatal acute coronary syndrome or stroke development: a case/case-control study.

New-onset extremely low levels of high-density lipoprotein cholesterol

Obstructive sleep apnoea syndrome and cardiovascular risk.

Pioglitazone and cancer: angel or demon?

Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia including Registries

Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?

Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia

Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose.

Statins and mortality: the untold story.

Statins and their increased risk of inducing diabetes

Targeting cardiovascular risk: the impact of age, gender and compliance to treatment

The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose.

The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

Therapeutic options for statin-intolerant patients

Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)

Variable effects of statins on glucose homeostasis parameters and their diabetogenic role.